Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023
2024

Nuvaxovid Vaccine Safety Profile in Australia

Sample size: 102946 publication 10 minutes Evidence: moderate

Author Information

Author(s): Hazel Clothier, Claire Parker, John Mallard, Paul Effler, Lauren Bloomfield, Dale Carcione, Jim Buttery

Primary Institution: Melbourne Children’s Campus, Melbourne, Australia

Hypothesis

What is the safety profile of the Nuvaxovid vaccine in a real-world setting after over 100,000 doses administered?

Conclusion

The analysis affirmed the safety profile of Nuvaxovid, showing mostly mild adverse events and no deaths attributable to vaccination.

Supporting Evidence

  • 356 adverse event reports were received following 102,946 doses administered.
  • Rates of adverse events were higher after the first dose compared to the second.
  • Serious adverse events included 94 cases of chest pain and two cases of myocarditis.

Takeaway

The Nuvaxovid vaccine is mostly safe, with only mild side effects reported after many doses given in Australia.

Methodology

A retrospective observational analysis of adverse events following immunisation reported to SAFEVAC from 14 February 2022 to 30 June 2023.

Potential Biases

Potential under-reporting and biases associated with spontaneous reporting systems.

Limitations

The study was based on enhanced spontaneous surveillance data, which may incur biases such as under-reporting.

Participant Demographics

Participants included individuals aged 6–97 years, with a higher reporting rate in females.

Statistical Information

P-Value

p=0.0008

Confidence Interval

95% CI: 1.2–2.0

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.2807/1560-7917.ES.2024.29.50.2400164

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication